Canada markets open in 5 hours 40 minutes

Deciphera Pharmaceuticals, Inc. (DCPH)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
13.73-0.25 (-1.79%)
At close: 04:00PM EDT
13.65 -0.08 (-0.58%)
After hours: 05:56PM EDT
Sign in to post a message.
  • D
    Davebiotech
    Jazz just paid RedRx $6mm for their preclinical Pan-Raf molecule with an option to license further. DCPH is well along in PI with DCC 3116 and has other Pan-Raf drugs in preclinical.
  • j
    josh
    Deciphera Pharmaceuticals, Inc. (DCPH) First Quarter 2022 Revenue of $29.2 Million

    Net Proceeds of $163.4 Million from Public Offering in April, Enabling the Company to Fund Operating and Capital Expenditures into 2025

    Phase 3 MOTION Study of Vimseltinib in TGCT Patients Underway; Updated Phase 1/2 Results Expected in 2H 2022

    Preclinical Data for DCC-3116 in Combination with KRASG12C Inhibitors Presented at the AACR Annual Meeting Demonstrating Deeper and Longer Tumor Regressions in Mutant KRASG12C NSCLC Models In Vivo

    Phase 1 Single Agent Dose Escalation Data for DCC-3116 Expected in 2H 2022

    New Development Candidate from Pan-RAF Research Program Expected in 2022
  • j
    josh
    Deciphera Pharmaceuticals beats by $0.08, beats on revs

    Reports Q1 (Mar) loss of $(0.80) per share, $0.08 better than the S&P Capital IQ Consensus of $(0.88); revenues rose 16.2% year/year to $29.22 mln vs the $27.17 mln S&P Capital IQ Consensus.Recorded $28.8 million in QINLOCK net product revenue in the first quarter of 2022, including $23.4 million in U.S. net product revenue and $5.4 million in international net product revenue.
  • o
    oliver
    The volume tells the whole story 😂 i was suspicious that something was coming down the pipeline but i didn't think it would b this bad
  • j
    josh
    Now is the time to Buy. News is out.. at $9.99 stock is a washed out time to buy DCPH
  • T
    Talibanpicks
    (KOD) Price $6.30 trading 50% UNDER Cash + 4x BIG Phase 3 near readouts for FREE = LIFETIME OPP !!!
    https://assets.wallstreet-online.de/_media/8763/board/20220317153902-screenshot-2022-03-17-at-15-12-40-powerpoint-pres.png

    ##
  • R
    Redposition
    I see it going to $30 again within the next 12 month !
  • y
    yass
    “The stock market is a device for transferring money from the impatient to the patient.”

    This company has solid foundations, efficient products and a huge new market with the European Commission approval. The coming reports will be a lot better. Hold on to your shares and be patient.
  • A
    Anonymous
    Hmm, shares up over 8% in the pre-market, with no news having hit the wires and no press release from the company, short of the one announcing the date of their quarterly report.
  • I
    Inam
    Buying at this price is a bargain. They have huge pipeline with already one drug approved and is bringing in 20-22 million dollars a quarter. This is a gem and will go higher in the coming weeks. They are waiting for the approval of their approved drug in EMA. I just reviewed their pipelines and it is very promising. Also they have 380 millions cash in their account.
  • J
    Jack
    That s good company to invest. It s just a barging price from $9 ..FDA approved drug,, EMU approval in 2 weeks time. 300M cash, good turnover about 80 M, and normal price range between $30-$40 and shorted very badly. Result report don't change anything for company because price already dropped from $60 to 30ish....So in a few week time price will go back over $20 very sure !!
  • D
    Davebiotech
    Finally read the transcript. Vimseltinib in TSGCT is an $850mm opportunity. Plus BID dosing for Quin puts drug at $24k/mo and docs likely to prescribe in 2nd line due to better ae's v sunitinib. With this, co has hi probability of $2bln revs in 2024 -2025 not counting the Pan Raf program.
  • M
    Max
    $12 soon?
  • M
    Mario
    Based on the current market we should all sit back have a drink and look forward to next hear. I wish all investors in DCPH a Great New Year! Stay Blessed!
  • P
    Pray22.88
    Sep 2017, DCPH IPOed with price over $19 and then the lowest price was around $15 in Oct 2017. Since then it had been consistently average in the 30's, even before QINLOCK got approved. Now with approved medicine and real revenue, and more from pipelines, it was under $20, way way way oversold! It is a steal at this price! Load it up and DOUBLE!
  • P
    Pray22.88
    https://www.tipranks.com/news/blurbs/leerink-partners-thinks-deciphera-pharmaceuticals-stock-is-going-to-recover-3

    Leerink Partners Thinks Deciphera Pharmaceuticals’ Stock is Going to Recover

    Leerink Partners analyst Andrew Berens maintained a Buy rating on Deciphera Pharmaceuticals (DCPH – Research Report) on November 30 and set a price target of $24.00.
    <p>Leerink Partners analyst <a href='https://www.tipranks.com/analysts/andrew-berens?ref=MCO_EXPERT' style='color:blue;' target='_blank' rel='nofollow'>Andrew Berens...</a>
    <p>Leerink Partners analyst <a href='https://www.tipranks.com/analysts/andrew-berens?ref=MCO_EXPERT' style='color:blue'; target= '_blank'; rel='nofollow'>Andrew Berens...
    www.tipranks.com
  • P
    Pray22.88
    Three major positive things from today's news:

    1. it provides clarity about its fiscal abilities and runway to 2024 which is excellent and anything could happen;

    2. it leads to better cash flows with increasing revenue from EU market and decreasing expenses;

    3. With fat trimmed, most importantly, it becomes a more attactive buy out target. Will not be surprised it could happen soon. I say price target around $15 or more!

    It is hard decision, but it sets DCPH on the right path!

    BUY!
  • H
    Hatteras
    they have cash but burning rate is very high, they would have cash for a year at the current rate with nothing to increase their revenues...
  • j
    josh
    * DECIPHERA PHARMACEUTICALS, INC. ANNOUNCES SECOND QUARTER 2021 FINANCIAL RESULTS

    * Q2 LOSS PER SHARE $1.21

    * Q2 REVENUE $23.6 MILLION VERSUS REFINITIV IBES ESTIMATE OF $21.9 MILLION

    * Q2 EARNINGS PER SHARE ESTIMATE $-1.16 -- REFINITIV IBES DATA

    * EXPECTS TO ANNOUNCE TOP-LINE RESULTS FROM INTRIGUE PHASE 3 STUDY IN Q4 OF 2021.
  • D
    Davebiotech
    Nice data showing Quinlock Ae's much less that sunitinib with comparable efficacy. Thus market share will increase for DCPH.